BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in

Status Completed

Clinical Trial Summary

Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC).

The BENEFIT study is being conducted by the Population Health Research Institute (in Hamilton, Canada) and the Institute Dante Pazzanese de Cardiologia (Sao Paulo, Brazil) together with a Steering Committee, and an independent Safety Monitoring Board.

Clinical Trial Description

A randomized double-blind controlled clinical trial investigating the role of benznidazole in patients with chronic Chagas' heart disease.

Chagas disease has 3 phases: acute, undetermined and chronic phases. There are no clinical trials up to date that have investigated the use of antiparasitic drugs in patients that are in the chronic phase.

This study will evaluate the efficacy and safety of benznidazole (an antiparasitic drug) in patients with chronic Chagas' heart disease. Evaluate if benznidazole, an antiparasite drug, given at a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg) - reduces morbidity and mortality in patients with Chronic Chagas' Cardiomyopathy (CCC). It will be developed in 49 study centres in Argentina, Bolivia,Brazil,Colombia, and El Salvador - countries with high incidence of Chagas Disease.

The Pilot study is evaluating if benznidazole is effective in producing parasitic cure (PCR negativization or reducing parasitic load) in chronic Chagas Disease as well as assessing the feasibility of conducting a large trial in chronic Chagas Disease in South America. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00123916
Study type	Interventional
Source	Population Health Research Institute
Contact
Status	Completed
Phase	Phase 3
Start date	November 2004
Completion date	August 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03481322` - Low Sodium Cooking Study	N/A
Completed	`NCT00001638` - Magnetic Resonance Imaging of the Blood Vessels of the Heart
Completed	`NCT02376244` - The Health Impact of High Intensity Exercise Training With Intervals During Cardiac Rehabilitation	N/A
Completed	`NCT02277379` - Prediction of Bleeding and Transfusion Outcomes and Assessment of Perioperative Platelet Reactivity in Cardiac Surgery	N/A
Completed	`NCT02523144` - Dexmedetomidine in Children Having Transthoracic Echocardiography	Phase 4
Completed	`NCT02045641` - Pleural and Pericardial Effusion Following Open Heart Surgery	N/A
Completed	`NCT01871090` - Remote Device Interrogation In The Emergency Department	N/A
Active, not recruiting	`NCT01400490` - Eicosapentaenoic Acid (EPA)and Docosahexaenoic Acid Study	N/A
Completed	`NCT01192360` - Dynamic Contrast Enhanced Magnetic Resonance Perfusion Imaging in Congenital Heart Disease and Lung Disease	Phase 3
Terminated	`NCT00935766` - Effect of Fish Oil (Omega-3 Fatty Acids) on Arteries	Phase 3
Completed	`NCT00745446` - The Effect of a Retrofit Particle Trap on the Vascular Effects of Diesel Exhaust Inhalation	N/A
Completed	`NCT00140816` - Dairy Products and Metabolic Effects (Norwegian Part)	N/A
Completed	`NCT00178620` - Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization	Phase 4
Completed	`NCT00013949` - Cardiovascular Vulnerability to Particulate Exposure	N/A
Completed	`NCT01952171` - The Genetic Basis of Congenital Heart Disease in Africa
Recruiting	`NCT02933892` - Benefit of Transradial Approach in Chronic Kidney Disease Population Undergoing Cardiac Catheterization	Phase 4
Withdrawn	`NCT02838355` - Employing End Tidal Capnography in Continuous Flow Ventricular Assist Device Patients	N/A
Completed	`NCT02923518` - Cardiac Screening of Middle Aged and Older Women and Men (Master Athletes)
Terminated	`NCT02282163` - Evaluation of Safety and Efficacy of Lumason in Pediatric Echocardiography	Phase 3
Active, not recruiting	`NCT02260466` - Prevalence and Post-surgical Outcomes of CARdiac Wild-type TransthyrEtin amyloidoSIs in Elderly Patients With Aortic steNosis Referred for Valvular Replacement.	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease — BENEFIT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms